康复新液与顺铂、伊立替康联用对大肠癌HCT116荷瘤小鼠肿瘤生长和造血系统的影响  

Impacts of Kangfuxin Decoction Combined with Cisplatin and Irinotecan on Cancer Cell Reproduction and Hemopoietic System in Tumor-Bearing Mice

作　　者：邹俊波[1] 熊永爱[1] 

机构地区：[1]成都中医药大学药学院中药材标准化教育部重点实验室四川省中药资源系统研究与开发利用重点实验室省部共建国家重点实验室培育基地,成都610075

出　　处：《世界科学技术-中医药现代化》2016年第5期854-862,共9页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：国家自然科学基金委青年项目(30902005):基于本草挖掘的中药药效物质基础与作用机理研究-蜣螂抗良性前列腺增生症的实验研究;负责人:谭承佳;四川省科技厅项目(2014TD0007):中药药理四川省青年科技创新研究团队;负责人:曾南

摘　　要：目的:考察康复新液与顺铂、伊立替康等用人结肠癌细胞HCT116荷瘤小鼠的联合用药效果。方法:SPF级C57BL/6小鼠110只,分别腹水接种HCT116制备种鼠模型,6-7天后,分离肿瘤组织制备HCT116荷瘤小鼠模型90只,随机分为模型组、康复新液组、顺铂组、康复新液联合顺铂组、伊立替康组、康复新液联合伊立替康组共6组,按实验方案给药16天,期间每3天测定一次动物体质量,16天后荷瘤小鼠摘眼球取血,测定血常规,处死后剥离肿瘤组织,测定肿瘤体积,计算小鼠FBW/IBW比值,分取骨髓,测定骨髓DNA含量,观察造血祖细胞集落,流式细胞仪检测骨髓细胞CD34+抗原的表达。结果:与模型组相比,各给药组瘤重均显著减轻(P<0.05),康复新液及联合用药组动物PLT、RBC、HGB水平均显著升高(P<0.05,P<0.01),顺铂组、伊立替康组小鼠血常规各项水平和骨髓DNA含量、造血祖细胞集落数量以及骨髓细胞CD34+抗原表达率均显著下降(P<0.05,P<0.01);与顺铂组、伊立替康组相比,与康复新液联合使用可明显抑制化疗药物导致的体质量下降(P<0.05),升高实验动物血常规水平(P<0.05,P<0.01),提升小鼠骨髓DNA含量、造血祖细胞集落数量以及骨髓细胞CD34+抗原表达率(P<0.05,P<0.01)。结论:康复新液具有明显抑制HCT116荷瘤小鼠肿瘤生长的作用,且与顺铂、伊立替康联合应用,可有效改善后二者引起的骨髓抑制作用,康复新液联合一线抗肿瘤药物的应用前景广阔。This study aimed to investigate the effects of Kangfuxin decoction（KFXD） combined with cisplatin and irinotecan on HCT116 cells reproduction and hemopoietic system in tumor-bearing mice. 110 C57BL/6 mice were implanted with HCT116 cells through abdominal injection, while 90 mice were randomly divided into the model group, the KFXD group, the cisplatin group, KFXD ＋ cisplatin group, the irinotecan group and KFXD ＋ irinotecan group. Mice of each group had been administered by corresponding medication for 16 days. The body weight were detected every 3 days. Blood routine examination were observed, while neoplastic tissues were separated and measured, FBW / IBW was counted, and DNA content of marrow, progenitor colony assay and expression rates of medullary cell CD34＋ were also measured and analyzed, respectively. It was found that in the medication groups the weights of neoplastic tissues were decreased compared with the model group（P〈 0.05）, while the levels of WBC, PLT, RBC and HGB of KFXD and the relevant combination groups were obviously increased（P 〈 0.05, P 〈 0.01, respectively）. Routine blood indexes, DNA content of marrow, progenitor colony assay and expression rates of medullary cell CD34＋ in the cisplatin group and the irinotecan group were decreased（P 〈 0.05, P 〈 0.01, respectively）. Compared with the cisplatin geoup and the irinotecan group, levels of PLT, RBC and HGB of relevant the combination groups were increased（P 〈 0.05, P 〈 0.01, respectively）, DNA content of marrow, progenitor colony assay and expression rates of medullary cell CD34＋ in the relevant combination groups were also increased（P 〈 0.05, P 〈 0.01, respectively）. It was concluded that KFXD inhibited the growth of HCT116 cells in the tumor tissues of mice, and improved the suppressant of bone marrow caused by cisplatin and irinotecan in the drug combination. The prospect of combination of KFXD and initial antitumor drugs were spacious.

关 键 词：康复新液 结肠癌 顺铂 伊立替康 联合用药 

分 类 号：R285.5[医药卫生—中药学]